Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus VESICARE.
LUSEDRA vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
5 mg orally once daily.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category C
Category C
Anticholinergic
Anticholinergic